Fulvestrant for the treatment of locally advanced or metastatic breast cancer

NICE technology appraisals [TA239] Published date:

NICE does not recommend fulvestrant instead of aromatase inhibitor drugs for postmenopausal women with locally advanced or metastatic breast cancer when the cancer:

  • depends on oestrogen for growth and
  • has returned or worsened after anti-oestrogen drugs.

Aromatase inhibitors and anti-oestrogens are types of drug used to treat breast cancer.

Why has NICE said this?

NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS. It was not clear from the evidence whether fulvestrant works as well as other treatments available on the NHS. It was also uncertain whether fulvestrant provides enough benefit to patients to justify its high cost, so NICE did not recommend it.

Get involved